I am a psychiatrist and the head of the outpatient unit of the Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland, whereas I also am appointed associate Professor in the Barbara Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY, USA. Over the past decade I have been working on big therapeutic drug monitoring (TDM) datasets for different neuropsychotropic agents including clozapine. I am member and vice-president of the task force for TDM of the German Collegium of Neuropsychopharmacology (AGNP), which regularly publishes updates of consensus works for TDM in Neuropsychopharmacotherapy.

Dr. Natella Rakhmanina is a Professor of Pediatrics at George Washington University and serves as an Associate Chief of the Division of the Pediatric Infectious Diseases and a Director of the HIV Prevention and Treatment Services at Children’s National Hospital in Washington, DC, USA. Dr. Rakhmanina obtained her MD degree at People’s Friendship University in Moscow, Russia, and her PhD degree in clinical pharmacology at the Erasmus University in Rotterdam, the Netherlands. For more than 25 years she has been providing care for infants, children and adolescents affected by the HIV epidemic. She is a successful clinical researcher, focusing her studies on the treatment and prevention of HIV in children and adolescents and serving as a principal investigator of NIH, CDC and industry funded pediatric and adolescent HIV studies. Dr. Rakhmanina has held multiple regional, national, and international professional roles including serving as immediate past Chair of the Committee on Pediatric AIDS at the American Academy of Pediatrics. For over a decade, she has been serving and continues to serve as a member of the US Department of Health and Human Services Panel on the Pediatric Antiretroviral Therapy and Management Guidelines at the Office of AIDS Research Advisory Council in National Institutes of Health and the Pediatric Advisory Working Group at the World Health Organization. She also has more than a decade experience in global health serving as a Senior Technical Advisor at Elizabeth Glaser Pediatrics AIDS Foundation where she led diverse projects on pediatric and adolescent HIV treatment in Sub-Saharan African countries.

Dr. Paul Thoueille is a clinical pharmacometrician and hospital pharmacist who completed his PhD in 2024. His main focus is the development of Therapeutic Drug Monitoring (TDM) as a tool for individualized dosage adjustment of drugs. He is an expert in population pharmacokinetic modelling, which he applied notably for the analysis of long-acting intramuscular antiretrovirals. He currently leads the TDM Unit at the Service of Clinical Pharmacology of the University Hospital of Lausanne, Switzerland.

Dr. Ethel D. Weld, MD, PhD is an assistant professor of medicine, pharmacology, and molecular sciences at the Johns Hopkins University School of Medicine. She earned her medical degree from the University of Chicago and her PhD in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health. She is board certified in Internal Medicine and Pediatrics and subspecialty board certified in Infectious Diseases and Clinical Pharmacology, and serves as an attending Infectious Diseases physician at the Johns Hopkins Hospital and the Johns Hopkins Bayview Medical Center. She is the recipient of Johns Hopkins Center for AIDS Research (CFAR) faculty retention funding, a CFAR Faculty Development Award for her study “Feasibility, Development and Validation of a Non‐cold‐chain‐requiring Assay to Measure Long‐acting Antiretrovirals in Blood”, and an NIH K23 mentored career award for her project entitled “Optimizing the Use of Long-Acting Antiretrovirals for Youth with HIV”. She chairs the IMPAACT 2005 and 2034 trials, both multi-site international studies of novel TB therapeutics in children. Her primary research focus is on developing HIV and TB therapeutics in special populations, and optimizing long-acting therapeutics for individuals with HIV and adherence challenges.